Alumis Inc., a clinical stage biopharmaceutical company, announced that it will present data on its oral therapy A-005, a selective TYK2 inhibitor, at the ACTRIMS Forum 2025 on February 28, 2025.

norda often finds its high-end trail running footwear compared to luxury automobiles, and Lamborghini is a constant descriptor. Though co-founder and CEO Nick Martire appreciates the craftsmanship and ...

Update: After a fitting on-trail debut at the Hardrock 100 ultramarathon followed by weeks of teasers and speculation, norda has officially unveiled the 005, a shoe the brand bills as the “ultimate ...